Advertisement
Research Article

Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration

  • Irving Kirsch mail,

    To whom correspondence should be addressed. E-mail: i.kirsch@hull.ac.uk

    Affiliation: Department of Psychology, University of Hull, Hull, United Kingdom

    X
  • Brett J Deacon,

    Affiliation: University of Wyoming, Laramie, Wyoming, United States of America

    X
  • Tania B Huedo-Medina,

    Affiliation: Center for Health, Intervention, and Prevention, University of Connecticut, Storrs, Connecticut, United States of America

    X
  • Alan Scoboria,

    Affiliation: Department of Psychology, University of Windsor, Windsor, Ontario, Canada

    X
  • Thomas J Moore,

    Affiliation: Institute for Safe Medication Practices, Huntingdon Valley, Pennsylvania, United States of America

    X
  • Blair T Johnson

    Affiliation: Center for Health, Intervention, and Prevention, University of Connecticut, Storrs, Connecticut, United States of America

    X
  • Published: February 26, 2008
  • DOI: 10.1371/journal.pmed.0050045

About the Authors

Irving Kirsch
Department of Psychology, University of Hull, Hull, United Kingdom
Brett J Deacon
University of Wyoming, Laramie, Wyoming, United States of America
Tania B Huedo-Medina, Blair T Johnson
Center for Health, Intervention, and Prevention, University of Connecticut, Storrs, Connecticut, United States of America
Alan Scoboria
Department of Psychology, University of Windsor, Windsor, Ontario, Canada
Thomas J Moore
Institute for Safe Medication Practices, Huntingdon Valley, Pennsylvania, United States of America

Corresponding Author

Email: i.kirsch@hull.ac.uk

Competing Interests

IK has received consulting fees from Squibb and Pfizer. BJD, TBH, AS, TJM, and BTJ have no competing interests.

Author Contributions

IK abstracted baseline data from the FDA dataset, conceived the analyses, analyzed the data, and wrote the initial draft. BJD established correspondence between trials reported in the FDA dataset and those reported in the GlaxoSmithKline clinical trial register, abstracted the data from those trials, checked baseline data for trials in the FDA dataset, identified published versions of the FDA trials, and abstracted the data from those trials. TJM obtained the data from the FDA, and TJM and AS abstracted improvement data from that dataset. TBH and BTJ joined the project during the review process, analyzed the data, and assisted with subsequent drafts of the manuscript.